Skip to main content
Clinical Trials/NCT05598307
NCT05598307
Recruiting
N/A

The Anesthetic and Analgesic Effects of Intravenous Magnesium Sulphate in Elective Laparoscopic Cholecystectomy

Aretaieion University Hospital1 site in 1 country90 target enrollmentJune 1, 2022

Overview

Phase
N/A
Intervention
magnesium bolus followed by normal saline infusion
Conditions
Pain, Postoperative
Sponsor
Aretaieion University Hospital
Enrollment
90
Locations
1
Primary Endpoint
pain score on arrival to Post-Anesthesia Care Unit (PACU)
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The aim of this double-blind randomized study will be to evaluate the effect an intravenous infusion of magnesium has on recovery outcomes after elective laparoscopic cholecystectomy

Detailed Description

Magnesium consists one of the most important electrolytes of the human body, producing effects in various systems, one of them being the central nervous system. It has been shown that the administration of intravenous magnesium sulphate during anesthesia can significantly reduce the requirements for anaesthetic and analgesic agents, perioperatively, and improve the quality of post anesthetic recovery. The present study will examine the effect of administering intravenous magnesium sulphate during anesthesia in patients undergoing elective laparoscopic cholecystectomy surgery. This is a single centre, double-blinded, randomised controlled trial in an adult population, taking place in a tertiary medical centre in Athens. The study consists of three comparison groups of equivalent population, produced by double blinded randomisation. Each comparison arm will be administered a different regimen of magnesium sulphate/placebo. During the perioperative time, depth of anaesthesia will be monitored using the Bispectral Index, (BIS™) and the nociceptive level with nociception level index (NOL®). Dosing of the anaesthetic agent, desflurane, as well as of the analgesic medication, remifentanil, will be adjusted according to the prior indices. Patients included in the study will be monitored in the PACU and the surgical ward for the first 24 hours, postoperatively. Primary outcomes include the requirements for anaesthetic and analgesic agents, time to emergence, time to extubation, time to recovery, quality of recovery variables, pain scores during the first 24 hours and adverse effects and/or complications of magnesium administration. Ethical approval for this trial has been granted by the Ethics Committee of the hospital.

Registry
clinicaltrials.gov
Start Date
June 1, 2022
End Date
June 1, 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Kassiani Theodoraki

Professor of Anesthesiology

Aretaieion University Hospital

Eligibility Criteria

Inclusion Criteria

  • Adult patents
  • American Society of Anesthesiologists (ASA) class I-III
  • elective laparoscopic cholecystectomy

Exclusion Criteria

  • body mass index (BMI) \>35 kg/m2
  • systematic use of analgesic agents preoperatively
  • chronic pain syndromes preoperatively
  • neurological or psychiatric disease on treatment
  • pregnancy
  • severe hepatic or renal disease
  • drug or alcohol abuse
  • language or communication barriers lack of informed consent

Arms & Interventions

magnesium bolus

A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, normal saline will be administered at a rate of 20 mL/h

Intervention: magnesium bolus followed by normal saline infusion

magnesium bolus and magnesium infusion

A bolus dose of magnesium of 40 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h

Intervention: magnesium bolus followed by magnesium infusion

placebo

100 mL of normal saline will be administered within 10 minutes preoperatively. Followingly, normal saline will be administered at a rate of 20 mL/h

Intervention: normal saline bolus followed by normal saline infusion

Outcomes

Primary Outcomes

pain score on arrival to Post-Anesthesia Care Unit (PACU)

Time Frame: immediately postoperatively

pain score by the use of Numeric Rating Scale (NRS) on arrival to PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

pain score at discharge from Post-Anesthesia Care Unit (PACU)

Time Frame: at discharge from Post Anesthesia Care Unit (PACU), approximately 1 hour postoperatively

pain score by the use of Numeric Rating Scale (NRS) at discharge from PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

pain score 24 hours postoperatively

Time Frame: 24 hours postoperatively

pain score by the use of Numeric Rating Scale (NRS) 24 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

Study Sites (1)

Loading locations...

Similar Trials